Literature DB >> 2459154

Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity.

B R Murphy1, E E Walsh.   

Abstract

The fusion (F) glycoprotein of respiratory syncytial virus (RSV) induces neutralizing antibodies and antibodies that inhibit fusion of infected cells (FI antibody). It was previously shown that infants and children immunized with Formalin-inactivated RSV 20 years ago developed antibodies that bound to the F glycoprotein but were deficient in neutralizing activity. A reexamination of these sera indicated that they were also deficient in FI activity. Thus, Formalin-inactivated RSV vaccine stimulated an unbalanced immune response in which an unusually large proportion of the induced antibodies were directed against nonprotective epitopes rather than against the epitopes that induce functional antibodies, i.e., neutralizing and FI antibodies. This deficiency in stimulation of functional antibodies probably decreased the protective efficacy of the vaccine and could have contributed to potentiation of disease in the vaccines during subsequent RSV infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459154      PMCID: PMC266671          DOI: 10.1128/jcm.26.8.1595-1597.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  13 in total

1.  Human respiratory syncytial virus glycoprotein G expressed from a recombinant vaccinia virus vector protects mice against live-virus challenge.

Authors:  E J Stott; L A Ball; K K Young; J Furze; G W Wertz
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

2.  Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection.

Authors:  H W Kim; J O Arrobio; C D Brandt; B C Jeffries; G Pyles; J L Reid; R M Chanock; R H Parrott
Journal:  Am J Epidemiol       Date:  1973-09       Impact factor: 4.897

3.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

4.  An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

Authors:  A Z Kapikian; R H Mitchell; R M Chanock; R A Shvedoff; C E Stewart
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

5.  Purification and characterization of the respiratory syncytial virus fusion protein.

Authors:  E E Walsh; M W Brandriss; J J Schlesinger
Journal:  J Gen Virol       Date:  1985-03       Impact factor: 3.891

6.  Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus.

Authors:  G A Prince; A B Jenson; V G Hemming; B R Murphy; E E Walsh; R L Horswood; R M Chanock
Journal:  J Virol       Date:  1986-03       Impact factor: 5.103

7.  Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.

Authors:  V A Fulginiti; J J Eller; O F Sieber; J W Joyner; M Minamitani; G Meiklejohn
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

8.  Expression of the fusion protein of human respiratory syncytial virus from recombinant vaccinia virus vectors and protection of vaccinated mice.

Authors:  G W Wertz; E J Stott; K K Young; K Anderson; L A Ball
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

9.  Administration of a highly attenuated, live respiratory syncytial virus vaccine to adults and children.

Authors:  P F Wright; R B Belshe; H W Kim; L P Van Voris; R M Chanock
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

10.  Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection.

Authors:  B R Murphy; B S Graham; G A Prince; E E Walsh; R M Chanock; D T Karzon; P F Wright
Journal:  J Clin Microbiol       Date:  1986-06       Impact factor: 5.948

View more
  86 in total

Review 1.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

Review 2.  How innate immune mechanisms contribute to antibody-enhanced viral infections.

Authors:  Sukathida Ubol; Scott B Halstead
Journal:  Clin Vaccine Immunol       Date:  2010-09-28

3.  Fixing a failed vaccine.

Authors:  Steven M Varga
Journal:  Nat Med       Date:  2009-01       Impact factor: 53.440

4.  The comparative genomics of human respiratory syncytial virus subgroups A and B: genetic variability and molecular evolutionary dynamics.

Authors:  Lydia Tan; Frank E J Coenjaerts; Lieselot Houspie; Marco C Viveen; Grada M van Bleek; Emmanuel J H J Wiertz; Darren P Martin; Philippe Lemey
Journal:  J Virol       Date:  2013-05-22       Impact factor: 5.103

5.  Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice.

Authors:  Leslie van der Fits; Renske Bolder; Marjolein Heemskerk-van der Meer; Joke Drijver; Yolinda van Polanen; Jan Serroyen; Johannes P M Langedijk; Hanneke Schuitemaker; Eirikur Saeland; Roland Zahn
Journal:  NPJ Vaccines       Date:  2020-06-12       Impact factor: 7.344

Review 6.  Immunity to human and bovine respiratory syncytial virus.

Authors:  T G Kimman; F Westenbrink
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

7.  Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.

Authors:  Eileen Goodwin; Morgan S A Gilman; Daniel Wrapp; Man Chen; Joan O Ngwuta; Syed M Moin; Patricia Bai; Arvind Sivasubramanian; Ruth I Connor; Peter F Wright; Barney S Graham; Jason S McLellan; Laura M Walker
Journal:  Immunity       Date:  2018-02-03       Impact factor: 31.745

8.  Respiratory syncytial virus vaccine: Is it coming?

Authors:  Valérie Sales; Elaine El Wang
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

9.  Enhancement of the CD8+ T cell response to a subdominant epitope of respiratory syncytial virus by deletion of an immunodominant epitope.

Authors:  Hoyin Mok; Sujin Lee; David W Wright; James E Crowe
Journal:  Vaccine       Date:  2008-07-26       Impact factor: 3.641

10.  Serum mannose-binding lectin levels are linked with respiratory syncytial virus (RSV) disease.

Authors:  Lucas Zimon Giacomini Ribeiro; Ralph A Tripp; Lívia Maria Gonçalves Rossi; Patrícia Vianna Bonini Palma; Jonny Yokosawa; Orlando Cesar Mantese; Thelma Fátima Mattos Oliveira; Lysa Luiz Nepomuceno; Divina Aparecida Oliveira Queiróz
Journal:  J Clin Immunol       Date:  2007-10-20       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.